Ascelia Pharma announces that the FDA has agreed to review the application for market approval of Orviglance. Read more.
C-ROW has completed a share buyback during week 46, 2025. Read more.
Coegin Pharma reached a milestone when the first Follicopeptide-powered product became available for consumer pre-orders on November 16th. Read more.
Diamyd Medicals phase III study for type 1 diabetes has passed the final safety review ahead of the early results reading in March 2026. Read more.
Egetis Therapeutics is ready for NDA application following positive results from the ReTRIACt study with Emcitate. Read more.
EQL Pharma has received marketing approval in Germany for Methenamine hippurate under the brand name Cystohipp. Read more.
Gabather has set the subscription price for the exercise of warrants of series TO 7 at SEK 0,025 per share ahead of the subscription period which begins on November 17, 2025. Read more.
Genetic Analysis announces the completion of the GA-map IBD Precision Dx biomarker panel. Read more.
Gradientech reaches important milestone as QuickMIC enters clinical routine in Austria. Read more.
Hamlet BioPharma has received pivotal status from the FDA for a pivotal phase III study in bladder cancer. Read more.
lundbeck is applying for marketing authorization in central Asian markets for Vyepti (eptinezumab) for the preventive treatment of migraine. Read more.
Oncoinvent announces that the subscription period for the rights issue has begun. Read more.
oriola is initiating change negotiations in connection with plans for a new distribution center in Finland. Read more.
Orion receives an award for international growth from the President of the Republic of Finland. Read more.
Ortivus informs about a possible mandatory bid from Ponderus Invest. Read more.
PExA reports that Sandra Lindstedts A research group in Lund has been granted 27 million SEK from the Swedish Cancer Foundation for early detection of lung cancer. Read more.
QLife updates on the reverse takeover process where the “Red Chip” structure will not be approved by Nasdaq and other structures are being explored. Read more.
SoftOx Solutions announces that GMP drug substance has been successfully produced. Read more.
Zenicor Medical Systems announces the outcome of the rights issue. Read more.
Insider trading & whistleblowing
Oncoinvent Oncoinvent (2)
Invitations & presentations
Communiqués
Reports
The latest from BioStock
» Zerion Pharma | Life Science Summit 2025
» Alligator Bioscience | Life Science Summit 2025
» Watch our webcast on the occasion of World Diabetes Day
» AI braces for a crash – biotech waits for retail to return
» European Patent Office gives green light for Isofol’s arfolitixorin
» ExpreS2ion signs global licensing agreement with Serum Institute of India